stock price today

What a way to start the week.  The markets are green right now and even ahead of all of the expected financial meetings this week, sentiment is high.  That’s true too for the companies we talked about this morning. So let’s dive in and get everyone caught up to speed.

ParcelPal Technology Inc. (PKG.CN) (PTNYF) Jumps On Integration News

ParcelPal Technology Inc. (PKG.CN) (PTNYF) has been on the move for most of the month and the recent jump comes on the heels of this penny stock announcing integration on the Shopify platform. If you’re wondering, this is the same Shopify that trades publicly at OVER $300 a share!

Now the deal was first scooped by Benzinga and was later confirmed when ParcelPal formally announced the deal later in morning. Businesses of any kind, notably cannabis merchants will be able to integrate their Shopify eCommerce store nearly instantly to ParcelPal’s ecosystem.

These merchants will enable their customers to tap into ParcelPal’s network and have their products delivered in an hour or less. ParcelPal has begun this process with Choom and Kiaro. You can read more about the ParcelPal/Shopify News Here. Since June 3, ParcelPal is up by more than 35% and we, for one, will continue to bring more updates as we find them.

GT Biopharma, Inc. (GTBP) Consolidation Could Lead To More Excitement

GT Biopharma, Inc. (GTBP) continues to pick up the pace.  Since we initiated coverage on the company, we’ve watch GTBP climb as much as 30% and as of today, it’s still up by roughly 12.5% in just over a week. We have seen a bit of consolidation to start this week but that could open the door to more excitement in June. The big focus for GTBP onlookers has been on its immunotherapy portfolio.

The bottom line here is that big money is pouring into cancer-focused companies specifically. The fact that as we write this, Pfizer is in the middle of an $11 billion dollar deal to buy a cancer therapy company should be even more proof of this focus.

To date, GT Biopharma has completed one dose escalation Phase I-II expansion clinical trial, and one fixed dose Phase I-II expansion clinical trial, which collectively enrolled a combined 43 patients. On the surface, the Phase I-II expansion clinical trial demonstrated greater than 50% of Evaluable patients receiving 60 mg/kg dose had a positive clinical response.

Two patients exhibited a Complete Remission with one patient currently disease-free at 50 months post-treatment. Additionally, five patients exhibited Stable Disease, cancers that are neither increasing nor decreasing in severity, with the longest response lasting 12 months post-treatment. In addition to this, the company’s therapy has also shown that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could be eliminated. We’ve put together a full report on GTBP so click here for more info.

Liberty Defense Holdings, Ltd. (SCAN.V) Surges On German Deal

We brought this back to the attention of our members earlier last week and since then things have been quite exciting to say the least. Here’s why: Liberty Defense was trading at CAD$0.69 and today we’ve witnessed a big boom to highs of $0.85 after making another big MOU announcement.  What was the news? Liberty Defense (SCAN.V) will be collaborating with FC Bayern München to beta test HEXWAVE. You can read the whole PR here.

This is what Bill Riker, CEO of Liberty Defense, said about this deal, “The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America. Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.”

stock price today
Disclaimer: MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.

Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 04/15/2018 – 5/15/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter now extended through June 21, 2019. We were paid $350,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

 Click Here For Full Disclaimer
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

The $40 Billion Dollar Content Gold Rush

Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing…

Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market

Technology has evolved over the years, and so have online websites and…

1 Biotech Stock is Positioning Itself for Success

Biotech has always been one of the best performing sectors in the market. A number of biotech stocks have produced life-changing returns because of their treatments and opportunities. You wont believe what this 1 stock is doing…

What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!

The opportunity for companies within this sector is massive we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.